{
    "clinical_study": {
        "@rank": "109196", 
        "acronym": "LOGIC", 
        "arm_group": [
            {
                "arm_group_label": "LGX818 + MEK162", 
                "arm_group_type": "Experimental", 
                "description": "Rational combination of LGX818 + MEK162"
            }, 
            {
                "arm_group_label": "LGX818 + LEE011", 
                "arm_group_type": "Experimental", 
                "description": "Rational combination of LGX818 + LEE011"
            }, 
            {
                "arm_group_label": "LGX818 + BGJ398", 
                "arm_group_type": "Experimental", 
                "description": "Rational combination of LGX818 + BGJ398"
            }, 
            {
                "arm_group_label": "LGX818 + BKM120", 
                "arm_group_type": "Experimental", 
                "description": "Rational combination of LGX818 + BKM120"
            }, 
            {
                "arm_group_label": "LGX818 + INC280", 
                "arm_group_type": "Experimental", 
                "description": "Rational combination of LGX818 + INC280"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of the Phase II CLGX818X2102 study is to assess the anti-tumor activity\n      of LGX818 in combination with selected agents."
        }, 
        "brief_title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "This is a phase II two part multi-center, open-label study. Part I: LGX818 single agent\n      treatment until progression Part II: Combination treatments of LGX818 + MEK162, or BKM120,\n      or BGJ398, or INC280, or LEE01 to assess the clinical efficacy, to further evaluate the\n      safety of the drug combinations in patients with locally advanced or metastatic BRAF mutant\n      melanoma after relapse on LGX818, and to determine the maximum tolerated dose of the\n      combinations (when not established previously). These drug combinations are selected and\n      assigned to patients based on documentation of molecular resistance mechanism.\n\n      Patients with BRAF mutant melanoma treated by LGX818 single agent in other studies can be\n      enrolled directly in Part II of CLGX818X2102 after relapse.\n\n      Dose-escalations in the combination arms for which no MTD has been established will be based\n      on the recommendations of a Bayesian logistic regression model guided by an escalation with\n      overdose control criterion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  locally advanced or metastatic melanoma\n\n          -  confirmed BRAF V600 mutation\n\n          -  patients na\u00efve to a selective BRAF inhibitor\n\n          -  fresh tumor biopsy at baseline, and patient agrees for a mandatory biopsy at the time\n             of relapse\n\n          -  life expectancy \u2265 3 months\n\n          -  World Health Organization (WHO) Performance Status \u2264 2.\n\n        Exclusion Criteria:\n\n          -  Previous treatment with RAF-inhibitor\n\n          -  Symptomatic or untreated leptomeningeal disease\n\n          -  Symptomatic brain metastases.\n\n          -  Known acute or chronic pancreatitis\n\n          -  Clinically significant cardiac disease\n\n          -  AST/SGOT and ALT/SGPT > 2.5 x ULN, or > 5 x ULN if liver metastases are present\n\n          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly\n             alter the absorption of oral interventional drug\n\n          -  Previous or concurrent malignancy.\n\n          -  Other severe, acute, or chronic medical or psychiatric condition or laboratory\n             abnormality that may increase the risk associated with study participation\n\n        Specific exclusion criteria for each treatment arm:\n\n        LGX818/MEK162:\n\n        History or current evidence of retinal disease History of Gilbert's syndrome.\n\n        LGX818/BKM120:\n\n        Patients with diabetes mellitus requiring insulin treatment Patient has mood disorders\n\n        LGX818/BGJ398:\n\n        History and/or current evidence of ectopic mineralization/ calcification Current evidence\n        of corneal disorder/ keratopathy Patients with current evidence of endocrine alteration of\n        calcium/phosphate homeostasis.\n\n        History of congenital long QT- syndrome and/or hypokalaemia CTCAE Grade \u2265 3 and/or\n        magnesium levels below the clinically relevant lower limits before study entry.\n\n        Ionized (i) calcium (Ca) > ULN Serum inorganic phosphorus (Pi) > ULN\n\n        LGX818/LEE011 History of congenital long QT- syndrome and/or hypokalaemia CTCAE Grade \u2265 3\n        and/or magnesium levels below the clinically relevant lower limits before study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820364", 
            "org_study_id": "CLGX818X2102", 
            "secondary_id": "2012-004798-17"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LGX818 + MEK162", 
                    "LGX818 + LEE011", 
                    "LGX818 + BGJ398", 
                    "LGX818 + BKM120", 
                    "LGX818 + INC280"
                ], 
                "description": "BRAF inhibitor", 
                "intervention_name": "LGX818", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LGX818 + MEK162", 
                "description": "MAPK1/2 inhibitor", 
                "intervention_name": "MEK162", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LGX818 + LEE011", 
                "description": "CDK4/6 inhibitor", 
                "intervention_name": "LEE011", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LGX818 + BGJ398", 
                "description": "FGFR inhibitor", 
                "intervention_name": "BGJ398", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LGX818 + BKM120", 
                "description": "Pi3K inhibitor", 
                "intervention_name": "BKM120", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LGX818 + INC280", 
                "description": "c-Met inhibitor", 
                "intervention_name": "INC280", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "open-label study;BRAF inhibitor;LGX818;MEK162;LEE011;BGJ398;BKM120;INC280;MAPK1/2 inhibitor; Pi3K inhibitor; FGFR; c-Met; CDK4/6; metastatic melanoma;BRAF; V600", 
        "lastchanged_date": "April 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "*see Various Departments*", 
                        "country": "United States", 
                        "state": "Arizona"
                    }, 
                    "name": "Mayo Clinic - Arizona Mayo"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles Onc Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute Onc Dept"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "sanchea2@mskcc.org", 
                    "last_name": "Armando Sanchez", 
                    "phone": "646-888-4339"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Dept Oncology"
                }, 
                "investigator": {
                    "last_name": "Michael K. Postow", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "CANN.askSarah@scresearch.net", 
                    "phone": "877-691-7274"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute Onc Dept"
                }, 
                "investigator": {
                    "last_name": "Jeffrey R. Infante", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt University Medical Center SC - Dept of Oncology ."
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "US Oncology Central Monitoring"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2145"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3002"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 3", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "80336"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zuerich", 
                        "country": "Switzerland", 
                        "zip": "8091"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Canada", 
                "France", 
                "Germany", 
                "Netherlands", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820364"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Incidence rate of Dose Limiting Toxicities (DLTs) in Cycle 1 of Combination Part (Part II)", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Plasma concentration and derived PK parameters of LGX818 and combination partners", 
                "safety_issue": "Yes", 
                "time_frame": "3years"
            }, 
            {
                "measure": "Overall Response Rate (ORR) (Part I)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Progression Free Survival (PFS)(Part I and II)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Duration Of Response (DOR) (Part II)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Overall Survival (OS) (Part II)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Molecular status (mutation/amplification/expression) of markers relevant to the RAF/MEK/ERK and PI3K/AKT pathways", 
                "safety_issue": "No", 
                "time_frame": "baseline, at progression with LGX818 single agent treatment up to 3 years"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}